Trump's April 2026 executive order supporting psychedelic drugs has boosted the psychedelics industry. The FDA awarded priority vouchers to select companies, accelerating drug review timelines. Three biotech firms—Compass Pathways, AtaiBeckley, and Definium Therapeutics—have seen significant stock surges. While analysts remain bullish with high upside targets, these remain speculative investments with substantial risks.

An executive order fast-tracking psychedelic medicines to market has bifurcated the alternative drug sector. Psychedelic stocks like Compass Pathways and Atai Beckley surged 40% and 20% respectively due to regulatory tailwinds and short squeezes, while mature cannabis operators like Curaleaf and Innovative Industrial Properties are now valued as stable, cash-generating businesses rather than speculative plays.

Compass Pathways stock surged over 40% following a White House Executive Order aimed at accelerating approval of psychedelic drug treatments for mental health. The company's COMP360 synthetic psilocybin therapy has completed two positive phase 3 trials for treatment-resistant depression and is now on a faster regulatory track with the FDA.

President Trump signed an executive order to fast-track FDA approval of psychedelic treatments for mental disorders, reducing review times from 6-10 months to 1-2 months. The order also allocates $50 million for private sector research. Three biotech companies with breakthrough therapy designations saw significant stock gains following the announcement.

Psychedelic therapy is emerging as a transformative treatment model for mental health conditions, particularly treatment-resistant depression and PTSD. Unlike daily medications, psychedelic therapy is an interventional approach administered 1-6 times with durable long-term benefits. Companies like Compass Pathways are advancing FDA trials, while the real investment opportunity may lie in the $10,000-$20,000 treatment services rather than just the drugs themselves. Big Pharma remains cautiously interested but not yet aggressively pursuing the space.

The psychedelic medicine sector is advancing with regulatory momentum, as the first psilocybin compound achieved two positive Phase 3 results in treatment-resistant depression. The DEA increased its 2026 psilocybin production quota by 67%. Five companies—Helus Pharma, Compass Pathways, Relmada Therapeutics, Alto Neuroscience, and Axsome Therapeutics—are progressing clinical programs targeting depression, anxiety, cognitive impairment, bladder cancer, and Alzheimer's agitation.

Compass Pathways stock surged 44% after announcing positive Phase 3 clinical trial results for COMP360, its psilocybin-based treatment for treatment-resistant depression. The company plans to submit a New Drug Application (NDA) to the FDA by the end of 2024, with trials involving over 1,000 participants showing statistically significant and clinically meaningful results.

Compass Pathways, a U.K.-based biotech company focused on psilocybin, has completed dosing in a late-stage clinical trial for its synthesized psilocybin treatment, COMP005. The company is testing the treatment on patients with moderate to severe depression who have not responded to previous treatments. Investors are hopeful for the success of this trial, as the field of psychedelic medicine is seen as having significant potential.

The depression treatment market is experiencing steady growth, driven by rising mental health awareness, increasing prevalence of depression, and advancements in novel therapies. The market is expanding with the introduction of innovative antidepressants, psychedelic-based treatments, and digital therapeutics.

Compass Pathways, a biotechnology company focused on mental health, announced its participation in several investor conferences in September 2024, including fireside chats and investor meetings.

Several biotechnology firms have psychedelic treatments in development, with promising results from clinical trials. The psychedelic market is expected to grow significantly, and most investors are favorable towards psychedelic stocks.

RBC Capital initiated coverage on Compass Pathways with an Outperform rating and a $23 price target, citing a high likelihood of positive phase III trial results for its psilocybin-based treatment for treatment-resistant depression and a potential peak revenue of $2.3 billion.